Shenzhen Capital Group Leads $28M Series B Round In Biotech Hrain Biotechnology

Shanghai-based oncotherapy-focused firm Hrain biotechnology Co., Ltd. announces on Monday that it raises RMB200 million (US$28 million) in a series B funding round led by venture capital firm Shenzhen Capital Group (SCG). Biomedicine-focused venture capital firm Yangming Kangyi, Xiamen-based investment firm Junchenda Capital, and Shenzhen-based investment firm ChiNext Qianhai Capital also participate in the round. […]

Shenzhen Capital Group Leads $28M Series B Round In Biotech Hrain Biotechnology comes originally from China Money Network. All Rights Reserved.

Read the original article: China Money Network